AURA 内在价值评估与基本面分析 - Aura Biosciences Inc

自选股列表管理

自选股列表

股价: 6.03 USD -1.79% 已休市

市值: $623.7百万

	Aura Biosciences Inc NASDAQ:AURA	US
B	Bossard Holding AG SWB:0B7	CH

内在价值

数据不足，无法可靠地计算 Aura Biosciences Inc 的内在价值。

我们的估值真的有效吗？查看回测结果 .

基本面分析

Aura Biosciences 做什么

生物技术 Health Care

Aura Biosciences是一家临床阶段生物技术公司，致力于开发在攻击肿瘤细胞的同时保留健康组织的癌症疗法。其主要疗法采用一种携带肿瘤靶向药物的病毒样颗粒，再通过光照激活，在非常精准的区域内破坏癌细胞。该公司以研究眼癌，尤其是葡萄膜黑色素瘤而闻名，但其更广泛的平台旨在治疗可通过局部方式触及并治疗的实体瘤。

总部: 美国 US
员工人数: 113
上市日期: 2021年10月29日

阅读完整公司概况

Aura Biosciences 如何赚钱

Cancer therapies

Aura Biosciences develops light-activated medicines that are designed to be injected into tumors and then triggered by a specific light source to kill cancer cells. Its work is centered on treating cancers such as eye and solid tumors that can be reached with this approach.

客户: Patients with specific cancers, treated through doctors and cancer centers that use Aura's medicines in clinical care or clinical trials.
收入模式: Aura is a development-stage biotech, so it has not built a broad product sales business. It would make money mainly by selling approved therapies through pharmaceutical distribution, and it may also earn research or licensing payments from partners.

查看公司概况